Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2014
Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapyCristina Saura, Johanna Bendell, Guy Jerusalem, et al.Blood|August 11, 2007
The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signalingPhilipp B Staber, Paul Vesely, Naznin Haq, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2011
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancerFred R Hirsch, Fairooz Kabbinavar, Tim Eisen, et al.The New England Journal of Medicine|June 30, 2016
Efficacy and Safety of Midostaurin in Advanced Systemic MastocytosisJason Gotlib, Hanneke C Kluin-Nelemans, Tracy I George, et al.The Journal of Experimental Medicine|February 1, 2006
Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutationsHanna S Radomska, Daniela S Bassères, Rui Zheng, et al.Future Oncology (London, England)|October 15, 2025
HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumorsThomas Powles, Aarti Bhatia, Barbara Burtness, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2025
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and ImmunotherapyConor E Steuer, Hidetoshi Hayashi, Wu-Chou Su, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2023
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II TrialIan E Krop, Norikazu Masuda, Toru Mukohara, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A Yu, Yasushi Goto, Hidetoshi Hayashi, et al.Nature Medicine|September 4, 2025
Patritumab deruxtecan in HR+HER2- advanced breast cancer: a phase 2 trialBarbara Pistilli, Fernanda Mosele, Noemie Corcos, et al.Pageof 2